表紙:抗真菌薬の世界市場-薬剤クラス別・適応症別・感染症タイプ別・投与経路別・エンドユーザー別・流通経路別・地域別:競争、予測および機会(2026年)SALE
市場調査レポート
商品コード
1030946

抗真菌薬の世界市場-薬剤クラス別・適応症別・感染症タイプ別・投与経路別・エンドユーザー別・流通経路別・地域別:競争、予測および機会(2026年)

Global Anti-Fungal Drugs Market, By Drug Class, By Indication, By Infection Type, By Route of Administration, By End User By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026

出版日: | 発行: TechSci Research | ページ情報: 英文 114 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

抗真菌薬の世界市場-薬剤クラス別・適応症別・感染症タイプ別・投与経路別・エンドユーザー別・流通経路別・地域別:競争、予測および機会(2026年)
出版日: 2021年10月01日
発行: TechSci Research
ページ情報: 英文 114 Pages
納期: 2-3営業日
担当者のコメント
2021年12月末までSingle User Licenseのディスカウントキャンペーンを実施中です。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗真菌薬市場規模は、2026年には284億8,469万米ドルに達するとみられ、予測期間中に10.39%のCAGRで成長すると予測されています。

予測期間における市場成長の主な要因は、真菌感染症の増加と考えられます。真菌感染症が人体に及ぼす悪影響に対する患者の意識の高まりが、世界中で抗真菌薬の需要を大きく促進しています。抗真菌薬を開発するための研究開発活動を促進するための政府資金や投資が増加していることも、市場の成長を後押ししています。

抗真菌薬の使用量の増加と、市販されている抗真菌薬の数の増加が、市場の需要を押し上げると予想されます。また、指や足の爪に感染する真菌症である「爪真菌症」の増加も、抗真菌薬の需要を高める大きな要因と考えられます。

当レポートでは、世界の抗真菌薬市場について調査しており、顧客の声、市場の見通し、市場力学、競合情勢など、包括的な情報を提供しています。

目次

第1章 製品の概要

第2章 調査手法

第3章 COVID-19が世界の抗真菌薬市場に与える影響

第4章 エグゼクティブサマリー

第5章 顧客の声

  • ブランド認知度
  • 真菌性疾患の有病率に寄与する要因
  • 一般的に観察される真菌症

第6章 世界の抗真菌薬市場の見通し

  • 市場規模と予測
    • 価値別
  • 市場シェアと予測
    • 薬剤クラス別(アゾール、エキノカンジン、ポリエン、アリルアミン、その他)
    • 適応症(カンジダ症、アスペルギルス症、ムコール症、皮膚糸状菌症、その他)
    • 感染症タイプ別(表在性真菌感染、全身性真菌感染)
    • 投与経路別(局所、経口、非経口、その他)
    • エンドユーザー別(ホームケア、病院、クリニック、その他)
    • 流通経路別(小売薬局、病院薬局、オンライン薬局)
    • 地域別
    • 企業別(2020年)
  • 製品市場マップ

第7章 北米の抗真菌薬市場の見通し

  • 市場規模と予測
    • 価値別
  • 市場シェアと予測
    • 薬剤クラス別
    • 適応症別
    • 感染症タイプ別
    • 投与経路別
    • エンドユーザー別
    • 流通経路別
    • 国別
  • 北米:国別分析
    • 米国の抗真菌薬市場の見通し
    • メキシコの抗真菌薬市場の見通し
    • カナダの抗真菌薬市場の見通し

第8章 欧州の抗真菌薬市場の見通し

  • 市場規模と予測
    • 価値別
  • 市場シェアと予測
    • 薬剤クラス別
    • 適応症別
    • 感染症タイプ別
    • 投与経路別
    • エンドユーザー別
    • 流通経路別
    • 国別
  • 欧州:国別分析
    • ロシアの抗真菌薬市場の見通し
    • ドイツの抗真菌薬市場の見通し
    • フランスの抗真菌薬市場の見通し
    • 英国の抗真菌薬市場の見通し
    • イタリアの抗真菌薬市場の見通し
    • スペインの抗真菌薬市場の見通し
    • ポーランドの抗真菌薬市場の見通し

第9章 アジア太平洋の抗真菌薬市場の見通し

  • 市場規模と予測
    • 価値別
  • 市場シェアと予測
    • 薬剤クラス別
    • 適応症別
    • 感染症タイプ別
    • 投与経路別
    • エンドユーザー別
    • 流通経路別
    • 国別
  • アジア太平洋:国別分析
    • インドの抗真菌薬市場の見通し
    • 中国の抗真菌薬市場の見通し
    • インドネシアの抗真菌薬市場の見通し
    • 日本の抗真菌薬市場の見通し
    • 韓国の抗真菌薬市場の見通し
    • マレーシアの抗真菌薬市場の見通し
    • オーストラリアの抗真菌薬市場の見通し

第10章 南米の抗真菌薬市場の見通し

  • 市場規模と予測
    • 価値別
  • 市場シェアと予測
    • 薬剤クラス別
    • 適応症別
    • 感染症タイプ別
    • 投与経路別
    • エンドユーザー別
    • 流通経路別
    • 国別
  • 南米:国別分析
    • ブラジルの抗真菌薬市場の見通し
    • コロンビアの抗真菌薬市場の見通し
    • アルゼンチンの抗真菌薬市場の見通し

第11章 中東およびアフリカの抗真菌薬市場の見通し

  • 市場規模と予測
    • 価値別
  • 市場シェアと予測
    • 薬剤クラス別
    • 適応症別
    • 感染症タイプ別
    • 投与経路別
    • エンドユーザー別
    • 流通経路別
    • 国別
  • 中東およびアフリカ:国別分析
    • ナイジェリアの抗真菌薬市場の見通し
    • トルコの抗真菌薬市場の見通し
    • 南アフリカの抗真菌薬市場の見通し
    • サウジアラビアの抗真菌薬市場の見通し
    • アラブ首長国連邦の抗真菌薬市場の見通し

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場の動向と展開

第14章 競合情勢

  • 競合の見通し
  • 企業プロファイル
    • Astellas Pharma Inc.
    • GlaxoSmithKline Plc
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd.
    • Gilead Sciences Inc.
    • Janssen Pharmaceuticals Inc.(Johnson & Johnson)
    • Pfizer Inc.
    • Sanofi S.A.
    • Merck & Co., Inc.
    • Glenmark Pharmaceuticals Ltd.
    • Sun Pharmaceuticals Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.(Mylan Laboratories Inc.)
    • Cipla Ltd.
    • Zydus Cadila Ltd.
    • Lupin Ltd.
    • Torrent Pharmaceuticals Ltd
    • Abbott Laboratories Inc
    • Novartis AG
    • Galderma SA

第15章 戦略的推奨事項

第16章 当社について・免責事項

図表

List of Figures

  • Figure 1: Global Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 2: Global Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 3: Global Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 4: Global Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 5: Global Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 6: Global Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 7: Global Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 8: Global Anti-Fungal Drugs Market Share, By Region, By Value, 2016-2026
  • Figure 9: Global Anti-Fungal Drugs Market Share, By Company, By Value, 2020
  • Figure 10: Global Anti-Fungal Drugs Product Market Map, By Value, 2016-2026F
  • Figure 11: North America Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 12: North America Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 13: North America Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 14: North America Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 15: North America Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 16: North America Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 17: North America Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 18: North America Anti-Fungal Drugs Market Share, By Country, By Value, 2016-2026F
  • Figure 19: United States Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 20: United States Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 21: United States Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 22: United States Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 23: United States Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 24: United States Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 25: United States Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 26: Mexico Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 27: Mexico Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 28: Mexico Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 29: Mexico Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 30: Mexico Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 31: Mexico Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 32: Mexico Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 33: Canada Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 34: Canada Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 35: Canada Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 36: Canada Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 37: Canada Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 38: Canada Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 39: Canada Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 40: Europe Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 41: Europe Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 42: Europe Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 43: Europe Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 44: Europe Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 45: Europe Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 46: Europe Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 47: Europe Anti-Fungal Drugs Market Share, By Country, By Value, 2016-2026F
  • Figure 48: Russia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 49: Russia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 50: Russia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 51: Russia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 52: Russia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 53: Russia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 54: Russia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 55: Germany Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 56: Germany Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 57: Germany Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 58: Germany Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 59: Germany Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 60: Germany Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 61: Germany Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 62: France Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 63: France Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 64: France Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 65: France Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 66: France Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 67: France Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 68: France Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 69: United Kingdom Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 70: United Kingdom Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 71: United Kingdom Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 72: United Kingdom Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 73: United Kingdom Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 74: United Kingdom Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 75: United Kingdom Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 76: Italy Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 77: Italy Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 78: Italy Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 79: Italy Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 80: Italy Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 81: Italy Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 82: Italy Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 83: Spain Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 84: Spain Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 85: Spain Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 86: Spain Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 87: Spain Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 88: Spain Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 89: Spain Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 90: Poland Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 91: Poland Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 92: Poland Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 93: Poland Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 94: Poland Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 95: Poland Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 96: Poland Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 97: Asia-Pacific Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 98: Asia-Pacific Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 99: Asia-Pacific Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 100: Asia-Pacific Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 101: Asia-Pacific Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 102: Asia-Pacific Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 103: Asia-Pacific Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 104: Asia-Pacific Anti-Fungal Drugs Market Share, By Country, By Value, 2016-2026F
  • Figure 105: India Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 106: India Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 107: India Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 108: India Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 109: India Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 110: India Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 111: India Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 112: China Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 113: China Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 114: China Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 115: China Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 116: China Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 117: China Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 118: China Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 119: Indonesia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 120: Indonesia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 121: Indonesia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 122: Indonesia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 123: Indonesia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 124: Indonesia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 125: Indonesia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 126: Japan Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 127: Japan Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 128: Japan Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 129: Japan Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 130: Japan Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 131: Japan Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 132: Japan Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 133: South Korea Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 134: South Korea Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 135: South Korea Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 136: South Korea Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 137: South Korea Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 138: South Korea Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 139: South Korea Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 140: Malaysia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 141: Malaysia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 142: Malaysia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 143: Malaysia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 144: Malaysia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 145: Malaysia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 146: Malaysia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 147: Australia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 148: Australia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 149: Australia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 150: Australia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 151: Australia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 152: Australia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 153: Australia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 154: South America Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 155: South America Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 156: South America Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 157: South America Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 158: South America Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 159: South America Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 160: South America Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 161: South America Anti-Fungal Drugs Market Share, By Country, By Value, 2016-2026F
  • Figure 162: Brazil Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 163: Brazil Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 164: Brazil Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 165: Brazil Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 166: Brazil Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 167: Brazil Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 168: Brazil Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 169: Colombia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 170: Colombia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 171: Colombia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 172: Colombia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 173: Colombia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 174: Colombia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 175: Colombia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 176: Argentina Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 177: Argentina Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 178: Argentina Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 179: Argentina Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 180: Argentina Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 181: Argentina Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 182: Argentina Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 183: Middle East and Africa Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 184: Middle East and Africa Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 185: Middle East and Africa Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 186: Middle East and Africa Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 187: Middle East and Africa Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 188: Middle East and Africa Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 189: Middle East and Africa Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 190: Middle East and Africa Anti-Fungal Drugs Market Share, By Country, By Value, 2016-2026F
  • Figure 191: Nigeria Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 192: Nigeria Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 193: Nigeria Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 194: Nigeria Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 195: Nigeria Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 196: Nigeria Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 197: Nigeria Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 198: Turkey Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 199: Turkey Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 200: Turkey Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 201: Turkey Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 202: Turkey Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 203: Turkey Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 204: Turkey Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 205: South Africa Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 206: South Africa Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 207: South Africa Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 208: South Africa Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 209: South Africa Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 210: South Africa Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 211: South Africa Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 212: Saudi Arabia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 213: Saudi Arabia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 214: Saudi Arabia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 215: Saudi Arabia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 216: Saudi Arabia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 217: Saudi Arabia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 218: Saudi Arabia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 219: UAE Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 220: UAE Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 221: UAE Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 222: UAE Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 223: UAE Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 224: UAE Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 225: UAE Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
目次
Product Code: 7786

Global anti-fungal drugs market is expected to reach USD28484.69 million by 2026, growing at CAGR of 10.39% over the forecast period. Fungal infections can lead to diseases including fungal pneumonia, candidiasis, mucormycosis, among others and these fungal infections require the dosage of anti-fungal drugs to ensure effective treatment. The increasing prevalence of fungal infections is considered the primary driver for the market growth in the forecast period. The rise in awareness levels among patients regarding the adverse effect of fungal infection on the human body is significantly accelerating the demand for anti-fungal drugs around the world. An increase in government funds and investments to promote research and development activities to formulate anti-fungal drugs is fueling the market growth. An increase in the use of anti-fungal drugs coupled with the rising number of anti-fungal drugs available over-the-counter is expected to boost the market demand. With the surge in popularity of over-the-counter drugs such as ketoconazole, miconazole, econazole, amorolfine, several patients are preferring over-the-counter drugs. The rise in onychomycosis cases, which is a fungal infection affecting fingers and toenails is also considered a major driver responsible for the high demand for anti-fungal drugs.

The global anti-fungal drugs market is segmented into drug class, indication, infection type, route of administration, end-user, distribution channel, regional distribution, and company. Based on drug class, market is further divided into azoles, echinocandins, polyenes, allylamines and others. The azoles segment is expected to dominate the anti-fungal drugs market in the forecast period owing to their use in treatment of almost all the indications. Based on indication, the market is segmented into candidiasis, aspergillosis, dermatophytosis, mucormycosis, and others. The candidiasis segment is expected to dominate the market owing to high cases globally associated with the fungal species.

Based on regional analysis, North America is expected to dominate the anti-fungal drugs market for the next five years owing to the presence of major market players in the region. The high prevalence of fungal infections in the region is another crucial factor aiding the market growth. Well-developed healthcare infrastructure and favorable government healthcare policies are the other significant factors bolstering the market growth.

The major players operating in the global anti-fungal drugs market are Astellas Pharma Inc., GlaxoSmithKline Plc, Bayer AG, Dr. Reddy's Laboratories Ltd., Gilead Sciences Inc., Janssen Pharmaceuticals Inc. (Johnson & Johnson), Pfizer Inc., Sanofi S.A., Merck & Co., Inc., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc. (Mylan Laboratories Inc.), Cipla Ltd., Zydus Cadila Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd, Abbott Laboratories Inc., Novartis AG, Galderma SA among others. Major companies are developing advanced technologies and launching new anti-fungal drugs to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments.

Years considered for this report:

Historical Years: 2016-2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022-2026

Objective of the Study:

  • To analyze the historical growth in the market size of global anti-fungal drugs market from 2016 to 2020.
  • To estimate and forecast the market size of global anti-fungal drugs market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast global anti-fungal drugs market based on drug class, indication, infection type, route of administration, end user, distribution channel, regional distribution, and company.
  • To identify dominant region or segment in the global anti-fungal drugs market.
  • To identify drivers and challenges for global anti-fungal drugs market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global anti-fungal drugs market.
  • To identify and analyze the profile of leading players operating in global anti-fungal drugs market.
  • To identify key sustainable strategies adopted by market players in global anti-fungal drugs market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global anti-fungal drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of various segments for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Anti-fungal drug manufacturing companies
  • Market research and consulting firms
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to anti-fungal drugs market

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global anti-fungal drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Anti-Fungal Drugs Market, By Drug Class:

Azoles

Echinocandins

Polyenes

Allylamines

Others

  • Global Anti-Fungal Drugs Market, By Indication:

Candidiasis

Aspergillosis

Mucormycosis

Dermatophytosis

Others

  • Global Anti-Fungal Drugs Market, By Infection Type:

Superficial Fungal Infection

Systemic Fungal Infection

  • Global Anti-Fungal Drugs Market, By Route of Administration:

Topical

Oral

Parenteral

Others

  • Global Anti-Fungal Drugs Market, By End-User:

Homecare

Hospitals

Clinics

Others

  • Global Anti-Fungal Drugs Market, By Distribution Channel:

Retail Pharmacy

Hospital Pharmacy

Online Pharmacy

  • Global Anti-Fungal Drugs Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • Russia
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Poland

Asia-Pacific

  • India
  • China
  • Indonesia
  • Japan
  • South Korea
  • Malaysia
  • Australia

South America

  • Brazil
  • Colombia
  • Argentina

Middle East & Africa

  • Nigeria
  • Turkey
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global anti-fungal drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Anti-Fungal Drugs Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Brand Awareness
  • 5.2. Factors Contributing to the Prevalence of Fungal Diseases
  • 5.3. Commonly Observed Fungal Diseases

6. Global Anti-Fungal Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others)
    • 6.2.2. By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others)
    • 6.2.3. By Infection Type (Superficial Fungal Infection v/s Systemic Fungal Infection)
    • 6.2.4. By Route of Administration (Topical, Oral, Parenteral, Others)
    • 6.2.5. By End User (Homecare, Hospitals, Clinics, Others)
    • 6.2.6. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)
    • 6.2.7. By Region
    • 6.2.8. By Company (2020)
  • 6.3. Product Market Map

7. North America Anti-Fungal Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Indication
    • 7.2.3. By Infection Type
    • 7.2.4. By Route of Administration
    • 7.2.5. By End User
    • 7.2.6. By Distribution Channel
    • 7.2.7. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Anti-Fungal Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Infection Type
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By End User
        • 7.3.1.2.6. By Distribution Channel
    • 7.3.2. Mexico Anti-Fungal Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Infection Type
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By End User
        • 7.3.2.2.6. By Distribution Channel
    • 7.3.3. Canada Anti-Fungal Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Infection Type
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By End User
        • 7.3.3.2.6. By Distribution Channel

8. Europe Anti-Fungal Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Indication
    • 8.2.3. By Infection Type
    • 8.2.4. By Route of Administration
    • 8.2.5. By End User
    • 8.2.6. By Distribution Channel
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Russia Anti-Fungal Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Infection Type
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By End User
        • 8.3.1.2.6. By Distribution Channel
    • 8.3.2. Germany Anti-Fungal Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Infection Type
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By End User
        • 8.3.2.2.6. By Distribution Channel
    • 8.3.3. France Anti-Fungal Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Infection Type
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By End User
        • 8.3.3.2.6. By Distribution Channel
    • 8.3.4. United Kingdom Anti-Fungal Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Infection Type
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By End User
        • 8.3.4.2.6. By Distribution Channel
    • 8.3.5. Italy Anti-Fungal Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Infection Type
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By End User
        • 8.3.5.2.6. By Distribution Channel
    • 8.3.6. Spain Anti-Fungal Drugs Market Outlook
      • 8.3.6.1. Market Size & Forecast
        • 8.3.6.1.1. By Value
      • 8.3.6.2. Market Share & Forecast
        • 8.3.6.2.1. By Drug Class
        • 8.3.6.2.2. By Indication
        • 8.3.6.2.3. By Infection Type
        • 8.3.6.2.4. By Route of Administration
        • 8.3.6.2.5. By End User
        • 8.3.6.2.6. By Distribution Channel
    • 8.3.7. Poland Anti-Fungal Drugs Market Outlook
      • 8.3.7.1. Market Size & Forecast
        • 8.3.7.1.1. By Value
      • 8.3.7.2. Market Share & Forecast
        • 8.3.7.2.1. By Drug Class
        • 8.3.7.2.2. By Indication
        • 8.3.7.2.3. By Infection Type
        • 8.3.7.2.4. By Route of Administration
        • 8.3.7.2.5. By End User
        • 8.3.7.2.6. By Distribution Channel

9. Asia-Pacific Anti-Fungal Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Indication
    • 9.2.3. By Infection Type
    • 9.2.4. By Route of Administration
    • 9.2.5. By End User
    • 9.2.6. By Distribution Channel
    • 9.2.7. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. India Anti-Fungal Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Infection Type
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By End User
        • 9.3.1.2.6. By Distribution Channel
    • 9.3.2. China Anti-Fungal Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Infection Type
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By End User
        • 9.3.2.2.6. By Distribution Channel
    • 9.3.3. Indonesia Anti-Fungal Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Infection Type
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By End User
        • 9.3.3.2.6. By Distribution Channel
    • 9.3.4. Japan Anti-Fungal Drugs Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By Infection Type
        • 9.3.4.2.4. By Route of Administration
        • 9.3.4.2.5. By End User
        • 9.3.4.2.6. By Distribution Channel
    • 9.3.5. South Korea Anti-Fungal Drugs Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Indication
        • 9.3.5.2.3. By Infection Type
        • 9.3.5.2.4. By Route of Administration
        • 9.3.5.2.5. By End User
        • 9.3.5.2.6. By Distribution Channel
    • 9.3.6. Malaysia Anti-Fungal Drugs Market Outlook
      • 9.3.6.1. Market Size & Forecast
        • 9.3.6.1.1. By Value
      • 9.3.6.2. Market Share & Forecast
        • 9.3.6.2.1. By Drug Class
        • 9.3.6.2.2. By Indication
        • 9.3.6.2.3. By Infection Type
        • 9.3.6.2.4. By Route of Administration
        • 9.3.6.2.5. By End User
        • 9.3.6.2.6. By Distribution Channel
    • 9.3.7. Australia Anti-Fungal Drugs Market Outlook
      • 9.3.7.1. Market Size & Forecast
        • 9.3.7.1.1. By Value
      • 9.3.7.2. Market Share & Forecast
        • 9.3.7.2.1. By Drug Class
        • 9.3.7.2.2. By Indication
        • 9.3.7.2.3. By Infection Type
        • 9.3.7.2.4. By Route of Administration
        • 9.3.7.2.5. By End User
        • 9.3.7.2.6. By Distribution Channel

10. South America Anti-Fungal Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Indication
    • 10.2.3. By Infection Type
    • 10.2.4. By Route of Administration
    • 10.2.5. By End User
    • 10.2.6. By Distribution Channel
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anti-Fungal Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Infection Type
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By End User
        • 10.3.1.2.6. By Distribution Channel
    • 10.3.2. Colombia Anti-Fungal Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Infection Type
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By End User
        • 10.3.2.2.6. By Distribution Channel
    • 10.3.3. Argentina Anti-Fungal Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Infection Type
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By End User
        • 10.3.3.2.6. By Distribution Channel

11. Middle East and Africa Anti-Fungal Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Indication
    • 11.2.3. By Infection Type
    • 11.2.4. By Route of Administration
    • 11.2.5. By End User
    • 11.2.6. By Distribution Channel
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. Nigeria Anti-Fungal Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Indication
        • 11.3.1.2.3. By Infection Type
        • 11.3.1.2.4. By Route of Administration
        • 11.3.1.2.5. By End User
        • 11.3.1.2.6. By Distribution Channel
    • 11.3.2. Turkey Anti-Fungal Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Indication
        • 11.3.2.2.3. By Infection Type
        • 11.3.2.2.4. By Route of Administration
        • 11.3.2.2.5. By End User
        • 11.3.2.2.6. By Distribution Channel
    • 11.3.3. South Africa Anti-Fungal Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Indication
        • 11.3.3.2.3. By Infection Type
        • 11.3.3.2.4. By Route of Administration
        • 11.3.3.2.5. By End User
        • 11.3.3.2.6. By Distribution Channel
    • 11.3.4. Saudi Arabia Anti-Fungal Drugs Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Drug Class
        • 11.3.4.2.2. By Indication
        • 11.3.4.2.3. By Infection Type
        • 11.3.4.2.4. By Route of Administration
        • 11.3.4.2.5. By End User
        • 11.3.4.2.6. By Distribution Channel
    • 11.3.5. UAE Anti-Fungal Drugs Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Drug Class
        • 11.3.5.2.2. By Indication
        • 11.3.5.2.3. By Infection Type
        • 11.3.5.2.4. By Route of Administration
        • 11.3.5.2.5. By End User
        • 11.3.5.2.6. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled
    • 14.2.1. Astellas Pharma Inc.
    • 14.2.2. GlaxoSmithKline Plc
    • 14.2.3. Bayer AG
    • 14.2.4. Dr. Reddy's Laboratories Ltd.
    • 14.2.5. Gilead Sciences Inc.
    • 14.2.6. Janssen Pharmaceuticals Inc. (Johnson & Johnson)
    • 14.2.7. Pfizer Inc.
    • 14.2.8. Sanofi S.A.
    • 14.2.9. Merck & Co., Inc.
    • 14.2.10. Glenmark Pharmaceuticals Ltd.
    • 14.2.11. Sun Pharmaceuticals Industries Ltd.
    • 14.2.12. Teva Pharmaceutical Industries Ltd.
    • 14.2.13. Viatris Inc. (Mylan Laboratories Inc.)
    • 14.2.14. Cipla Ltd.
    • 14.2.15. Zydus Cadila Ltd.
    • 14.2.16. Lupin Ltd.
    • 14.2.17. Torrent Pharmaceuticals Ltd
    • 14.2.18. Abbott Laboratories Inc
    • 14.2.19. Novartis AG
    • 14.2.20. Galderma SA

15. Strategic Recommendations

16. About Us & Disclaimer